MARKET

BPMC

BPMC

Blueprint
NASDAQ

Real-time Quotes | Nasdaq Last Sale

93.88
-2.57
-2.66%
Closed 16:02 05/17 EDT
OPEN
95.00
PREV CLOSE
96.45
HIGH
96.95
LOW
93.27
VOLUME
272.69K
TURNOVER
--
52 WEEK HIGH
125.61
52 WEEK LOW
60.82
MARKET CAP
5.48B
P/E (TTM)
16.64
1D
5D
1M
3M
1Y
5Y
Blueprint Medicines names Percy Carter as chief scientific officer
Blueprint Medicines (BPMC) announces the appointment of Percy Carter as the company's chief scientific officer, effective May 19, 2021.Carter brings more than 20 years of pharmaceutical company and industry experience, and prior to joining
Seekingalpha · 20h ago
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Percy Carter, MBA, Ph.D., as Chief Scientific Officer, effective May 19, 2021. In this role, Dr. Carter will oversee all of the company's research and preclinical development...
PR Newswire · 20h ago
BRIEF-Cstone Pharmaceuticals Announces Acceptance Of New Drug Application For Avapritinib
reuters.com · 5d ago
Gastrointestinal Stromal Tumor (GIST) Drug Market Size 2021: Top Countries Data with Segmentation, Production, Revenue, Gross Margin Analysis and Forecast 2027
May 07, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The Global "Gastrointestinal Stromal Tumor...
The Express Wire · 05/07 08:14
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on May 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 21,045 shares of its common...
PR Newswire · 05/05 21:01
Xilio Therapeutics Appoints Christina Rossi to Its Board of Directors
Xilio Therapeutics, a biotechnology company developing, tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Christina Rossi, chief commercial officer of Blueprint Medicines, as a member of its board o...
BusinessWire · 05/05 10:30
Leerink Partners Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)
In a report issued on April 29, Andrew Berens from Leerink Partners reiterated a Buy rating on Blueprint Medicines (BPMC), with a price target of $127.00.
SmarterAnalyst · 05/03 11:50
Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag
Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.
Zacks · 04/30 14:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BPMC. Analyze the recent business situations of Blueprint through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BPMC stock price target is 117.83 with a high estimate of 152.00 and a low estimate of 81.00.
EPS
Institutional Holdings
Institutions: 387
Institutional Holdings: 61.90M
% Owned: 106.09%
Shares Outstanding: 58.34M
TypeInstitutionsShares
Increased
77
2.46M
New
24
142.58K
Decreased
63
828.27K
Sold Out
26
322.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
Daniel Lynch
President
Fouad Namouni
Executive Vice President
Tracey Mccain
Chief Executive Officer/Director
Jeffrey Albers
Chief Financial Officer
Michael Landsittel
Chief Operating Officer
Kathryn Haviland
Chief Human Resource Officer
Debra Durso-Bumpus
Executive Vice President
Anthony Boral
Senior Vice President
Christopher Murray
Chief Scientific Officer
Marion Dorsch
Chief Compliance Officer
Tracey McCain
Vice President/Controller
Ariel Hurley
Other
Becker Hewes
Other
Christina Rossi
Director
Alexis Borisy
Independent Director
Lonnel Coats
Independent Director
George Demetri
Independent Director
Mark Goldberg
Independent Director
Nicholas Lydon
Independent Director
Charles Rowland
Independent Director
Lynn Seely
No Data
  • All
  • Financials
  • Insiders
More
About BPMC
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Webull offers kinds of Blueprint Medicines Corp stock information, including NASDAQ:BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.